GlycoMimetics (GLYC) Tops Q2 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. META
3. ANT
4. SPY
5. CART
6. FFAI
7. TSLA
8. FFR
9. AZN
10. GMAB

Go back to GlycoMimetics (GLYC) Tops Q2 EPS by 8c

GlycoMimetics (GLYC) to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at ASH

November 6, 2019 10:04 AM EST

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that seven abstracts covering data from the companys research and clinical portfolio have been accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 7-10, 2019 in Orlando.

Of particular note, clinical data from the Companys recent Phase 1/2 study of uproleselan, an E-selectin antagonist and the companys lead wholly owned clinical candidate, were selected for a poster presentation on Sunday, December 8 during a session on biology of AML. The presentation will feature data showing uproleselans ability... More